Yes. Orthopedic surgeons are more aware of surgical treatment of osteoporotic fractures in the past decade; however, this is not the same for the medical treatment. [1] In Turkey, the majority of patients presenting with osteoporotic hip and vertebra fractures are underevaluated and undertreated for the prevention of secondary fractures. [2] The cumulative incidence of secondary hip fractures has been reported to be 9% in the Netherlands. [3] The relatively high risk of sustaining secondary hip fractures highlights the importance of secondary prevention in patients with a prior wrist or vertebral fracture.
The World Health Organization (WHO) developed the Fracture Risk Assessment Tool (FRAX), a tool used for the osteoporotic fracture risk assessment.
[4] However, we still believe that the FRAX tool has serious limitations for some countries. [5] Furthermore, the definition of osteoporosis based on T-score on bone mineral density measurement is no longer sufficient. [6] Therefore, the following question should be answered: Which subgroups of patients with low-energy fractures are eligible to undergo anti-osteoporotic drug therapy? The answer is simple:
• If the patient has low-energy distal radius fracture, be alert to spinal or hip fractures,
• If the patient has low-energy spinal or hip fracture, be aware of further spinal or secondary hip fractures, and
• Start anti-osteoporotic drug therapy!
